Compare Ford Motor Company (F) vs Moderna, Inc. (MRNA) Price & Performance

Ford Motor Company (F) trades at $12.25, down 0.2% with bearish technical signals. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Despite $187.3B revenue in 2025, net income was -$8.18B with negative margins. Analyst consensus is mixed with 38% buy ratings and a $15.90 price target. Recent news highlights sales declines and production challenges, though the company maintains strong cash flow from operations.

Ford faces significant headwinds including declining sales, negative profitability, and high debt levels. The stock offers value with low P/E (11.21) and P/S (0.26) ratios, but execution risks and competitive pressures from Asian automakers pose challenges. The dividend provides income support, but investors should weigh fundamental weaknesses against valuation appeal.

Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.

Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.